Citigroup’s Thorne Healthtech, Inc. Common Stock THRN Stock Holding History

Citigroup’s Portfolio THRN Stock Details THRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15	Closed	-$153	–	5962
2023 Q3	$153	Sell	15 -4,173	-100%	-$31.8K	﹤0.01%	5350
2023 Q2	$19.7K	Buy	4,188 +4,187	+418,700%	+$19.2K	﹤0.01%	4960
2023 Q1	$5	Sell	1 -93	-99%	-$409	﹤0.01%	5428
2022 Q4	$341	Sell	94 -116	-55%	-$514	﹤0.01%	5549
2022 Q3	$1K	Sell	210 -814	-79%	-$4.09K	﹤0.01%	5729
2022 Q2	$5K	Buy	1,024 +761	+289%	+$4.63K	﹤0.01%	5644
2022 Q1	$2K	Sell	263 -2,865	-92%	-$15.4K	﹤0.01%	6113
2021 Q4	$19K	Buy	+3,128	New	+$24.4K	﹤0.01%	5403

Citigroup's THRN Position: Q4 2023 in Review

Citigroup sold out of Thorne Healthtech, Inc. Common Stock (THRN) in Q4 2023, closing a stake of 15 shares — an estimated $153 sold.

Citigroup first reported a position in THRN in Q4 2021 and held it in 8 quarters. The position peaked at $19.7K in Q2 2023. 0 funds tracked by Wall St. Rank hold THRN as of Q4 2023.

Citigroup reported no remaining Thorne Healthtech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Citigroup sold 15 Thorne Healthtech, Inc. Common Stock shares in Q4 2023, an estimated $153.
Citigroup first reported a position in Thorne Healthtech, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Citigroup's Thorne Healthtech, Inc. Common Stock position peaked at $19.7K in Q2 2023.
0 funds tracked by Wall St. Rank held Thorne Healthtech, Inc. Common Stock as of Q4 2023.

Based on Citigroup's 13F filing for Q4 2023, filed 9 Feb 2024.